Common Contracts
2 similar Underwriting Agreement contracts by Mabvax Therapeutics Holdings, Inc.
MABVAX THEREAPEUTICS HOLDINGS, INC. 1,127,859 Shares of Common Stock 665,281 Shares of Series F Convertible Preferred Stock Class A Warrants to Purchase up to 1,793,140 Shares of Common Stock Class B Warrants to Purchase up to 1,793,140 Shares of...Underwriting Agreement • August 17th, 2016 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Laidlaw & Company (UK) Ltd. (the “Underwriter”), an aggregate of (i) 1,127,859 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of the Company, (ii) 665,281 authorized but unissued shares (the “Preferred Shares”) of preferred stock, par value $0.01 per share, designated as Series F Preferred Stock (the “Preferred Stock”), to have the relative rights, preferences, limitations and designations set forth in the Certificate of Designation filed as an exhibit to the Registration Statement (as defined below) (the “Certificate of Designation”), and to be convertible into an aggregate of 665,281 shares of Common Stock (the “Conversion Shares”), (iii) Class A warrants (the “Firm Class A Warrants”) to purchase up to an aggregate of 1,793,140 shares of Common Stock (the “Firm
ContractUnderwriting Agreement • August 3rd, 2016 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
